Illumina (NASDAQ:ILMN) CEO Jay T. Flatley sold 30,000 shares of Illumina stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $154.95, for a total value of $4,648,500.00. Following the transaction, the chief executive officer now directly owns 381,262 shares of the company’s stock, valued at approximately $59,076,547. Illumina, Inc. (NASDAQ:ILMN) net profit margin is 13.80% and weekly performance is 10.54%. On last trading day company shares ended up $159.20. Analysts mean target price for the company is $176.97. Illumina, Inc. (NASDAQ:ILMN) distance from 50-day simple moving average (SMA50) is 9.16%.
Alnylam Pharmaceuticals (NASDAQ:ALNY) Director John K. Clarke sold 35,000 shares of the company’s stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $53.80, for a total value of $1,883,000.00. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares advanced 5.78% in last trading session and ended the day on $58.75. ALNY return on assets is -55.00%.Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) quarterly performance is -32.99%.
Regeneron Pharmaceuticals (NASDAQ:REGN) major shareholder Sanofi bought 190,751 shares of the company’s stock in a transaction that occurred on Monday, May 19th. The shares were purchased at an average price of $300.04 per share, for a total transaction of $57,232,930.04. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shares moved down -0.17% in last trading session and was closed at $297.77, while trading in range of $293.63 – $299.56. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) year to date (YTD) performance is 8.19%.
Stemline Therapeutics (NASDAQ:STML) COO Kenneth Hoberman sold 15,250 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $13.32, for a total transaction of $203,130.00. Following the completion of the sale, the chief operating officer now directly owns 87,535 shares in the company, valued at approximately $1,165,966. Stemline Therapeutics Inc. (NASDAQ:STML) ended the last trading day at $13.84. Company weekly volatility is calculated as 9.75% and price to cash ratio as 7.51.Stemline Therapeutics Inc. (NASDAQ:STML) showed a positive weekly performance of 7.37%.
Leave a Reply